Drug Trial Radar · NCT07658339
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
387
Planned (sponsor's estimate)
Start
Jul 11, 2026
Primary completion
Jun 11, 2027
Study completion Jun 11, 2027
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of HSK39004 Inhalation Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
HSK39004 Inhalation SuspensionDrug
Dosage Formulation: HSK39004 Inhalation suspension Dosage 3mg,Twice Daily for 24 weeks
Placebo controlDrug
Dosage Formulation: Placebo Inhalation suspension Dosage 0mg,Twice Daily for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12Time frame: Baseline (pre-dose on Day 1) and Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.